CompletedNCT02704065
Recurrent AA Amyloidosis After Renal Transplantation
Studying AA amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Istanbul University
- Principal Investigator
- Yasar Caliskan, MDDivision of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
- Enrollment
- 54 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2016
Study locations (4)
- Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa, Turkey (Türkiye)
- Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey (Türkiye)
- Division of Nephrology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul, Turkey (Türkiye)
- Division of Nephrology, Sisli Hamidiye Etfal Training and Education Hospital, Istanbul, Turkey (Türkiye)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02704065 on ClinicalTrials.govOther trials for AA amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06974877Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid LoadNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT06354322Unclassified GENotypes of Autoinflammatory Diseases and AA AmyloidosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT04265040DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research StudiesUniversity Hospital Heidelberg
- ACTIVE NOT RECRUITINGNANCT03584022Clinical Trial to Assess the Safety of a Novel Scaffold BiomaterialMayo Clinic